BTIG Remains Positive on NeoGenomics (NEO) Following Q4 Results, Guidance; Affirms at 'Buy'
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
NeoGenomics Reports Record Revenue of $27.2 Million and Record Adjusted EBITDA of $2.9 Million in Fourth Quarter, Driven by Strong Volume Gains
March 1, 2016 7:01 AM ESTFT. MYERS, Fla., March 1, 2016 /PRNewswire/ --Â NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of cancer-focused genetic testing services, today reported its results for the fourth quarter and full year 2015.
Fourth Quarter 2015 Highlights:
25% growth in base(1) test volume 12% reduction in Avg. Cost-per-test in base(1) business Record Adjusted EBITDA(2) of $2.9 million (even with $2.1 million of FISH reductions) Adjusted Diluted EPS(2) of $0.05 per share and Diluted EPS of ($0.03) per shareFull Year 2015 Highlights:
25% growth... More